TABLE 2.

Geometric mean activities measured by the different assaysa

Sample group (no. of samples)bGeometric mean activity (95% CI)
Serion PT IgG (FDA U/ml)Pert FHA IgG (% of cutoff)Pert FHA IgA (% of cutoff)Pert PT IgG (% of cutoff)Pert PT IgA (% of cutoff)OPA against live bacteria (titer)C3b against live bacteria (AU/ml)IgG against live bacteria (AU/ml)
1 (92)4.9 (4.1, 5.9)126.1 (113.1, 140.4)54.6 (49.3, 60.6)101.0 (92.1, 110.8)82.5 (76.6, 88.8)49.2 (38.1, 63.5)232.6 (206.0, 262.6)62.6 (50.1, 78.3)
2 (89)47.7 (45.2, 50.5)246.6 (229.1, 265.5)92.0 (80.1, 105.7)267.4 (255.4, 279.9)80.5 (75.2, 86.2)227.8 (185.8, 279.2)520.3 (435.8, 621.1)375.4 (291.6, 483.2)
3 (67)150.9 (135.3, 168.1)309.5 (283.5, 337.9)125.8 (108.0, 146.4)491.8 (466.2, 518.7)91.4 (83.8, 99.8)429.4 (343.6, 536.7)1,031.0 (799.2, 1,330.0)843.4 (620.4, 1,146.0)
  • a Pert, Pertusscan.

  • b All 248 serum samples (124 paired serum samples) were sorted by IgG anti-PT levels from the Serion assay. Groups were defined as described in footnote b of Table 1.